ParagonDx Gets FDA OK for Warfarin Kit | GenomeWeb
NEW YORK (GenomeWeb News) – ParagonDx said today that it has received US Food and Drug Administration clearance to market its rapid genotyping assay for warfarin sensitivity.
The pharmacogenomic test provides information about the CYP2C9 and VKORC1 genotypes and is used to identify patients that are at greater risk for warfarin sensitivity. ParagonDx claimed in a statement that its product is the first cleared genotyping assay to deliver results in less than an hour and incorporate human genomic quality controls.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.